Meet our team leaders
Alain Lamproye joined Yposkesi as CEO in January 2017. Previously, he served as President of the BioPharma Business Unit of Novasep from 2012 to 2017, as well as CEO of its subsidiary dedicated to gene therapy (Henogen, Belgium). Between 2003 and 2012 he held various managerial positions in pharmaceutical operations at Merck Serono, including serving as Site Director at Billerica (USA). He previously worked as GMP Production Director at Eurogentec (Belgium) for 14 years. Alain holds a M.S. in biology from the University of Liège (Belgium).
Armandine Bonnet joined Yposkesi as General Counsel in September 2018. Previously, she served for two years as Vice-President Legal Affairs of DBV Technologies, a Nasdaq and Euronext-listed biopharmaceutical company, where she built and led the worldwide legal and compliance functions of the company. Prior to that, she successively held the positions of General Counsel of the German generic producer Ratiopharm for over three years and of Pharnext, a French biotechnology company. From 1999 to 2006, Armandine Bonnet practiced as a corporate attorney at the international law firm Landwell (PwC). She was admitted to the Paris Bar in 1999 and received an LLM in international business law from King’s College London (UK).
Olivier Courné joined Yposkesi in 2016 as a Technical Director. With over 17 years’ experience in the pharmaceutical industry in the production of parenteral products, Olivier began his career in the automotive industry. For 9 years, has was the head of maintenance and HSE, for which he contributed to the construction and operation of a fuel tank production site. In 1999, Olivier joined an ORGANON production site where he structured maintenance activities and maintenance methods. In 2010, he joined a MSD site in animal health, to take over maintenance activities. Olivier holds a degree in Industrial Maintenance Management.
Philippe Cuif joined Yposkesi as Chief Information Officer in 2019. With 25 years’ experience in IT management working with international groups, Philippe held various positions in IT management. Before joining Yposkesi, he was European IT manager of Vetoquinol, a French veterinary pharmaceutical laboratory, where he managed the company global IT system. He began his career in networking and communication in the automotive industry where he successively held positions of Networks Architect and IT infrastructure manager, contributing to the merger and integration of several subsidiaries IT systems. He holds a degree in computer engineering and a degree in management of information systems.
Morad El Gueddari
Morad El Gueddari joined Yposkesi as Head of Operations in 2018. Morad has 15 years’ bioproduction and cell and gene therapy experience gained in various managerial roles in quality and GMP manufacturing at European pharmaceutical companies, including LFB and CELLforCURE (now part of Novartis). Dr. El Gueddari holds a PharmD from the Limoges, France Pharmacy School.
Jean-Xavier Gaillat joined Yposkesi as Quality Director/Qualified Person in 2019. Jean-Xavier has to close to 15 years’ experience in the pharmaceutical manufacturing, gained in various managerial roles in quality, in particular for GSK and Sanofi. Before joining Yposkesi, he used to lead the quality department of a large scale FDA approved CMO site. Jean-Xavier holds a PharmD from the University of Clermont-Ferrand, France and an engineer degree from the Ecole des Mines of Albi, France both obtained in 2007.
Patrick Lansky joined Yposkesi as VP of US Sales and Marketing in 2019. Patrick has worked in various positions in the life sciences for the past 25 years before joining Yposkesi. He started his career working at Idec Pharmaceuticals where he spent 5 years learning the ins and outs of protein development and manufacturing. Patrick then moved to the business side of the industry where he spent 8 years selling single-use systems for Stedim. He then spend 10 years developing business for a gene and cell therapy CMO. Patrick holds a BS in Physiology and Neuroscience from UC San Diego and currently resides in La Jolla, CA.
Erwan Martin joined Yposkesi as Secretary General in 2019. With over 20 years’ of experience in the biotechnology and medical technology industries, Erwan is an expert in finance and corporate development. After starting his career in an audit and consulting firm, he co-founded Cytomics Pharmaceuticals, a biotechnology company specialized in the discovery of new medicines, where he was a member of the Management Board and Chief Financial Officer. He supported the Company’s development, overseeing several financing rounds worth a total of more than €20 million. In 2009 Erwan became Chief Financial Officer of Genomic Vision (Euronext: GV) and VP Corporate Development until 2017, undertaking financing operations such as the Company’s initial public offering in 2014. Before joining Yposkesi he was the Group Chief Financial Officer of Cellnovo Group (Euronext: CLNV), a medical technology company in the diabetes space. Erwan Martin holds an MBA from Warwick Business School (UK) and is a graduate of the Ecole Supérieure de Commerce (ESC) of Toulouse.
Isabelle Moghimi-Colin joined Yposkesi as Human Resources Director in 2016. With 20 years’ HR management experience, Isabel held various HR managerial positions in the service, oil and pharmaceutical industries, within companies such as Motul and MSD France (Merck Group). Isabelle holds a Master degree in political science and business law from the University of Paris I & V and a Master degree in Human Resources from the Paris conservatory for continuing adult education (CNAM).
Brian Mulan joined Yposkesi as Chief Technical Officer in 2020. With over 20 years’ experience working with large multinational companies, including big pharma, Brian has held leadership roles in late phase process development, product launch, commercial supply, process optimization and troubleshooting, and post-approval change management in multiple global markets for therapeutic monoclonal antibodies. He spent the last eight years at Novartis, where he held posts as head of manufacturing science and technology and as a global technical project leader. Between 2008 and 2012, he was process tech transfer lead at Eli Lilly. Prior to that, he worked at Centocor Biologics for nearly three years and Sanofi-Aventis for close to four years. He holds a PhD in Viral Genetics from University College Cork obtained in 2001 and an MBA from the Open University Business School in 2011. He conducted industrial post-doctoral work in gene therapy vectors – Adenoviral and Adeno-Associated Virus (AAV) at Sanofi-Aventis.
Christel Rivière, PhD, joined Yposkesi in 2016 as Director of CMC project management. With over 20 years’ experience in the gene therapy field, she started her career at the Gene Therapy R&D organization Genethon, where she managed process & analytical development of AAV and LV vectors. She also contributed to the implementation of CDMO activities within Genethon with external partners and clients. Christel holds a PhD in Oncology from the University of Paris XI.
Fabien Zugmeyer joined Yposkesi in 2016 as a Strategic Project Investment Director. With 25 years’ experience in bioproduction and cell and gene therapy gained in various managerial roles in quality, product project management and engineering projects management at biopharmaceutical companies, Fabien previously worked at several companies including Genethon and Transgene. Fabien holds a Master’s degree in Engineering from the University of Strasbourg (France).
Prof. José Alain Sahel
President Department of Ophthalmology – University of Pittsburgh
Prof. Ophthalmology – University Pierre-et-Marie-Curie Paris
Prof. Biomedical Siences – Institute of Ophthalmology, « University College Cumberlege », London
Prof. Alain Fischer
Director – Founder, Institute Imagine, Hôpital Necker-Enfants Malades, AP-HP, Paris, France
Professor Collège de France
Member of the National Medicine Academy USA
Dr. Serge Braun
Scientific Director AFM-Telethon
Member of the French Pharmacy Academy